Selumetinib gets Breakthrough Therapy Designation
1 April 2019 07:00 BST Selumetinib granted US Breakthrough TherapyDesignation in neurofibromatosis type 1 Designation based on Phase II SPRINT trial inpaediatric patients with NF1 plexiform neurofibromas Selumetinib is a MEK 1/2 Inhibitor being co-developed by AstraZeneca and MSD AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the MEK 1/2 inhibitor and potential new medicine selumetinib. This